MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13075-018-1772-z

Медицинская библиотека · Arthritis research & therapy · 2019

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.

Gratacós Jordi, Pontes Caridad, Juanola Xavier, Sanz Jesús, Torres Ferran, Avendaño Cristina, Vallano Antoni, Calvo Gonzalo, de Miguel Eugenio, Sanmartí Raimon, REDES-TNF investigators

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАEquivalence TrialПеревод в очереди

Аннотация

OBJECTIVE

The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis.

METHODS

Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded.

RESULTS

The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) - 2.5% (- 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164).

CONCLUSION

In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses.

TRIAL REGISTRATION: EU Clinical Trials Registry, EudraCT 2011-005871-18 and ClinicalTrials.gov, NCT01604629 .

Для цитирования: Gratacós Jordi, Pontes Caridad, Juanola Xavier, Sanz Jesús, Torres Ferran, Avendaño Cristina, Vallano Antoni, Calvo Gonzalo, de Miguel Eugenio, Sanmartí Raimon, REDES-TNF investigators. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.. Arthritis research & therapy. 2019. DOI: 10.1186/s13075-018-1772-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.